CNTNAP1 and chronic myelogenous leukemia, BCR-ABL1 positive: In order to elucidate these findings, Gong et al. analyzed the risk and frequency of blast transformation, response to treatment with TKIs, and clinical outcomes in 2322 treated CML patients and corresponding transcripts, with the intention to elucidate the differences between e1a2 transcripts (p190) and the more common p210 breakpoint [15].